ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
|Articles|January 10, 2019
Selexis Expands Immuno-Oncology Alliance with Agenus
Author(s)BioPharm International Editors
Agenus will leverage Selexis’ SUREtechnology Platform to progress Agenus’ portfolio of next-generation antibody programs.
Advertisement
Selexis, a provider of mammalian cell-line development technology, announced on Jan. 9, 2019 that it has signed additional commercial license agreements (CLAs) with Agenus, a clinical-stage immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, and adoptive cell therapies.
Under the new CLAs, Agenus will leverage Selexis’ modular SUREtechnology Platform for the production of its therapeutic proteins. Selexis reports that its SUREtechnology Platform improves the way mammalian cells are used in the discovery, development, and manufacturing of recombinant proteins and drugs. The platform comprises four major components: whole genome sequencing and bioinformatics, advanced gene transfection technology for procedures, media and feed strategies, and a proprietary Chinese hamster ovary (CHO)-K1 cell line. Selexis reports that the platform provides significant advantages over traditional approaches that enable speed, high-yield, stability, and flexibility.
Headquartered in Lexington, MA, Agenus focuses on combination approaches for antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies through its AgenTus Therapeutics subsidiary. The company has a suite of antibody discovery platforms and a GMP manufacturing facility with the capacity to support early phase clinical programs.
“Our fully integrated capabilities, from early discovery of protein therapeutics to GMP manufacturing, allows us to rapidly produce and clinically test promising new drug candidates thereby delivering innovation with speed. A critical step in this process is the in-house development of commercially viable cell-lines expressing novel and complex proteins,” said Alex Duncan, PhD, chief technology officer at Agenus, in the release. “We have successfully used the Selexis’ platform to drive our lead anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) programs and are excited to partner with them to advance our novel single agent and multi-specific antibody programs.”
Source:
Advertisement
Related to this article
UCB will use Cradle’s AI-driven protein design platform in selected discovery projects, from hit generation through preclinical readiness, expanding its digital antibody engineering program.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5